Navigation Links
Kerala Drafts a New Health Tourism Policy

A new health tourism policy from Kerala promises heavy investment opportunities for Non-Resident Keralites (NRK), making it a reliable venture ensuring steady returns in the// long term.

Kerala Tourism Department has planned for an investor meet in Kochi from March 23 – 27 for showcasing the opportunities in the health tourism sector. The meet is expected to be a congregation of major hospitals, health insurance companies, policy makers and international institutions for promotion of health tourism.

Tourism Minister Kodiyeri Balakrishnan said the government would extend all help to NRK investors who venture to set up health care centres, be it allopathy, ayurveda or nature cure. But only hospitals that conform to stipulations of the National Accreditation Board for Hospitals and Health Providers would qualify for Government recognition.

The government is partnering the Confederation of Indian Industry in making health care the State’s new offering to the international community and It has been declared that 2006-07 the Medical Tourism Year in Kerala.
SR
'"/>




Page: 1

Related medicine news :

1. Kerala Government is in High Alert for Bird Flu
2. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
3. Brain drain of dentists from Kerala to Britain
4. Three meals daily Keeps Keralas elderly Healthy
5. Couple infected with HIV marry in Kerala
6. International conference on Ayurveda to be held on Kerala
7. Kerala Bans The Sale Of Pan Masala Near Schools
8. Kerala To Become Testing Center For US Bound Nurses
9. Kerala Leads In The Health Sector
10. Mutton And Beef Sellers Rule The Roost In Kerala
11. Nine National Birds found dead in Tamil Nadu-Kerala Border
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Kerala Drafts New Health Tourism Policy

(Date:10/8/2008)... Dr. Paul Parker is pleased to announce enha...computer imaging for http://www.parkercenter.net/...oplasty in New Jersey]. Paramus plastic surgeon, ...raw attention to itself but rather complement othe...ll appearance, gender and ethnicity." , ...
(Date:10/8/2008)... Gastorenterologist Dr. Patricia Raymond off... East Longmeadow, MA (PRWEB) Octob...sary. In fact, the average person passes gas about...three liters daily). However, every body behaves d...s. If you are one of those unlucky few, follow the...
(Date:10/8/2008)... AccurateAnswers™ support program prov...r http://www.appointment-plus.com [online schedu... Scottsdale, AZ (PRWEB) October 8, 2008 -- Appoi...duling software, continues to expand its software ...t "software as a service" providers are ...
(Date:10/7/2008)... Merck KGaA (EMD in North America) announced...iance with Nano-Terra, Inc., a leading nanotechnol... DARMSTADT, Germany (Business Wire EON) Octob...companies, announced in February 2007, was to deve...solutions based on Merck,s materials. , , , After ...
Breaking Medicine News(10 mins):Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 2Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 3Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 4Health News:Managing Gas Isn't Rocket Science 2Health News:Managing Gas Isn't Rocket Science 3Health News:Appointment-Plus Continues Innovation With Technical Support Program 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 3
...a study published in the August issue of Neurology...ents are admitted to and discharged from the hospi...icantly. Studies have shown that several treatment...ount of disability, complications and the risk of ...
...a recent study researchers say that they found tha...te tumour cells in laboratory settings. Scientist...state cancer // could be due to a rapid increase i... the western diet in recent years. Omega-6 fats ha...
...shown that the efficacy of low-carb diets could be...chers question whether raising protein intake coul...esearchers set out to test the hypothesis that inc...bohydrate intake decreases the appetite, leads to ...
...he century started with a big bang, bringing hope ...ever, fate and nature had ideas of their own. 20...isasters and man made ones. The first internatio... February 1st in California when a jet bound for S...
Other Medicine News:Health News:Simple Procedural Improvements Can Improve Care Of Stroke Patients 2Health News:Finding The Key To Weight Loss! 2Health News:SARS (Bird Flu) spreading in the Asian continent 2
(Date:10/7/2008)...Prevented Immunologic Changes Induced by ...itional Data Indicates Potential in Treating Infla...ewswire/ -- Alba Therapeutics Corporation,presente...he American,College of Gastroenterology (ACG) 2008...001-004, the first Phase IIa trial conducted in ce...
(Date:10/7/2008)... ACG Annual Scientific Meeting -, ORLANDO, Fla., ...uticals, Inc. (formerly Microbia, Inc.) and Forest...the presentation of results from a Phase,2b study ... patients with,irritable bowel syndrome with const...at once- daily oral dosing of linaclotide, across ...
(Date:10/7/2008)...d Placebo-Controlled Phase II Study Shows ...al., MOUNTAIN VIEW, California, October 7 /PRNews...he mature Phase II data from the,therapeutic prost... been,obtained as part of the recently entered par...in the US., The results from the Phase II prospec...
(Date:10/7/2008)... /-, - 125 Patient, Prospe...,Shows Statistically Significant Improved Overall ...ature phase II data from the,therapeutic prostate ...n,obtained as part of the recently entered partner...he US., The results from the Phase II prospective...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Cultures role on alcohol and violence 26970 1Cultures role on alcohol and violence 26970 2Forest Laboratories Inc Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 8032 1Forest Laboratories Inc Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 8032 2Invest in Kids Rally to Be Held Before St Louis Vice Presidential Debate 26966 1Invest in Kids Rally to Be Held Before St Louis Vice Presidential Debate 26966 2The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 1The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 2The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 3The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 4The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 5
...ire-FirstCall/ -,Neurochem (International) Limited...em Inc. , announces that the New England,Journal o...rodisate,For AA Amyloidosis Trial" (EFAAT), recogn...r a treatment of AA amyloidosis. The,results of th...TA(TM)) demonstrate that this product candidate of...
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
Other Medicine Technology:Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 2Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 3Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 4Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: